Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. - Wikidata - wikimedia - TriplyDB

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

http://www.wikidata.org/entity/Q40529844

about

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status Prostate-specific membrane antigen as a target for cancer imaging and therapy Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095.Diagnostic performance of 68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients.The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer.TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer Initial Evaluation of [(18)F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Nanoparticle-Enabled Selective Destruction of Prostate Tumor Using MRI-Guided Focal Photothermal Therapy.Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.The dog prostate cancer (DPC-1) model: a reliable tool for molecular imaging of prostate tumors and metastases.[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA)Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates Biodistribution and radiation dosimetry for a probe targeting prostate-specific membrane antigen for imaging and therapy Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer.68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience.Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival.Synthesis and pre-clinical evaluation of a new class of high-affinity 18F-labeled PSMA ligands for detection of prostate cancer by PET imaging.Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer Vectors for the delivery of radiopharmaceuticals in cancer therapeutics.PET-based molecular imaging in personalized oncology: potential of the assessment of therapeutic outcome.Next revolution in molecular theranostics: personalized medicine for urologic cancers.Prostate Cancer Imaging with Novel PET Tracers.Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs.Small Molecules for Active Targeting in Cancer.The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer.PSMA PET and Radionuclide Therapy in Prostate Cancer.Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy.Design of Internalizing PSMA-specific Glu-ureido-based Radiotherapeuticals.Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing.Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.Biodistribution of [(68)Ga]PSMA-HBED-CC in Patients with Prostate Cancer: Characterization of Uptake in Normal Organs and Tumour Lesions.Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617.Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.Comparison of [(18)F]DCFPyL and [ (68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer.Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer.

P2860

Q26774920-2000E3EA-6733-4268-A60C-B9C45E448432 Q26799439-41B49F6F-A463-4B7D-9FC7-89B96AEADC14 Q33581903-A34BD31D-B5E7-4AFA-94C7-FA1A98E5D0FE Q33841484-6BF545E3-B750-49E0-812F-440FB08F2F46 Q35043569-D0E2AD09-A629-4D3C-B744-74CDDFC42048 Q35828584-887BF58C-9F1E-40C1-AD9F-D1F46095A2E0 Q35938051-63F7B8B0-D519-47E1-A7A8-C7472CB6A5AF Q36023165-C72CCBB8-94A1-4ED6-A38C-F247D39B557A Q36128368-BA97243E-19F8-4EEF-B774-81497AE6AF22 Q36415375-BD4545FD-D3BB-41F3-9DD9-C6C749CD5DC3 Q36867784-A00F59CD-22F7-421E-B584-C34CD7D7753A Q36928870-A1819999-FBEE-4CD7-B53C-C7F120591F29 Q37214430-9438B225-B0DD-48F5-9679-349665BE16C3 Q37390674-907A73A1-AF4F-4FBA-9EF9-8DDB27D1E92E Q37554235-A6C16654-6149-4BE5-B76A-EC93465A2CB1 Q37662701-36F0B050-F39C-48AF-A1F3-A12AF89A00FD Q37662752-25669BCB-A303-4401-B0E9-233A2834694B Q37709519-9292474C-A190-4873-BBCA-37743A84F1E7 Q38261959-1228CD57-39EF-44ED-A4F8-AC5C126DEBF1 Q38389152-F7C20A7B-1831-4381-9493-7D4EF0B721DD Q38559336-F501180F-CF14-481E-80B2-F19E710CF478 Q38732369-847A7882-F9E9-4029-94C9-4FF78C72D1FF Q38773634-258FD92C-F88D-4B99-BE09-8447B5C00350 Q38780383-F2738B36-A8C6-499D-BA38-2F2833C2AC28 Q38831232-BC90F5E6-62D2-4A34-BE50-0A73194360AA Q38861197-A33EBBF3-CA3D-43BB-8C3B-49FA49C552C5 Q38966705-437AC6FB-A69A-4348-ABE4-75F2F2025453 Q38982670-B3287580-731F-4AD3-8E11-0BA46B4AAE77 Q39003089-845BC63C-896F-49A4-A1CF-3D3D4926F9BC Q39183360-769882B7-8C8F-4486-9D53-FFD6AB18DCDB Q39697612-0A7C0C4B-CBC7-4933-A07E-7FF466E43ECB Q39710843-A77DC3BC-0CC6-49BE-8B78-1E0F980520A3 Q39780216-E59524A8-721E-4B76-A642-72F2D699957D Q39828822-940B0A6C-66D5-41A1-BF39-5688DAE62AA6 Q39869574-8383950E-0121-4A6D-91B6-955CD96EF60E Q40208178-8BBF5691-4592-49CA-913C-8D10832269A3 Q40913769-266E4A5A-8EC8-416A-A2F6-4BA6570C0B6D Q41319390-E55A12A3-6FC4-4351-9641-C3254623A0EE Q41475179-880C319F-282A-4CFC-AA64-3FA661709B86 Q41582278-DCDFAF3E-A614-444D-9AAE-9CEC3FAA008F

P2860

Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy.

http://www.wikidata.org/entity/Q40529844

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Radiation dosimetry and first ...... A for prostate cancer therapy.

@en

type

label

Radiation dosimetry and first ...... A for prostate cancer therapy.

@en

prefLabel

Radiation dosimetry and first ...... A for prostate cancer therapy.

@en

P1433

Q40529844-15778A55-264E-4B71-941E-6494B58D48E5

P1476

Q40529844-A720133D-BA32-48CE-B293-E57A01166749

P2093

Q40529844-09881777-F0AA-4FA7-9314-0AD2EAD48740

Q40529844-54D8F33F-EDEC-43A5-A0C7-168BAD2AFE1B

Q40529844-85E24471-F83A-45CA-AAF6-EE309EA5B0B5

Q40529844-A9EE04B3-D309-4B75-93B7-E13B023CF4EE

Q40529844-AAFCD356-D7FD-40FB-8A18-7FD81F2EE5DE

Q40529844-F17F15DE-798F-44E9-8546-49104821B01D

P2860

Q40529844-00B51400-5C3C-4BED-AF51-AC76D3F0CA3C

Q40529844-109299D2-668D-4B19-8561-1C4BAC55D7FF

Q40529844-15C4A496-A344-42AB-A188-C65C0D379BE4

Q40529844-3052301D-DDA0-46AB-BDC2-21724E81CF4C

Q40529844-35E662C0-054E-462E-A4FE-B7B900A8F8D0

Q40529844-40E3496B-189F-4C06-A9F7-1626BDDA6B4C

Q40529844-52C30273-7A07-4882-AC07-C1774CCE1C2B

Q40529844-59578C2D-4EFE-4A4B-884C-10039A87BFCD

Q40529844-706D3DAA-C794-4FE2-9172-BF66E7AC89B0

Q40529844-81317F0A-7D72-44EE-BDCB-9C035E1DEF02

P2888

Q40529844-4719D398-4BD6-42E1-846B-ABB761B83088

P304

Q40529844-CFA1CA27-EFB8-4551-97BB-DD19E2B3E38F

P31

Q40529844-B974A829-1054-48B8-B805-0721464B638F

P356

Q40529844-CA1452CC-4E56-4F4C-A2B1-A10AEEE174CF

P433

Q40529844-A2C3E5CF-CA4F-459C-B6A7-8C6E63D7EF82

P478

Q40529844-6CA1FC82-AB1D-4F6B-9493-FDFD6BE74171

P50

Q40529844-297F7263-8737-49FD-BC58-3ACE006B4256

Q40529844-3B761372-9482-4A52-9BD9-51757F0C1A00

Q40529844-8F66D5C3-952C-4403-9DA1-A2E7DFDAEA7A

Q40529844-A359D0AF-026F-4F83-8A53-AD349F87B69B

Q40529844-A6BFCAC1-1DB1-480C-84F9-F0D04CE14B34

P577

Q40529844-D556B7B7-EA1B-478B-9305-1954AFC3AF9E

P5875

Q40529844-AD0702DA-73F7-426B-9F68-A4C7A9A02A3C

P698

Q40529844-25B69BA2-3ADF-4B5E-9DC4-9B18FA276B48

P921

Q40529844-98BF0F1E-D697-4C97-9C47-286C28123E50

P932

Q40529844-743A975D-0EAB-43AE-A560-12338D7D20BA

P356

S00259-014-2713-Y

P1433

European Journal of Nuclear Medicine and Molecular Imaging

P1476

Radiation dosimetry and first ...... A for prostate cancer therapy.

@en

P2093

James B Stubbs

http://www.w3.org/2001/XMLSchema#string

John Joyal

http://www.w3.org/2001/XMLSchema#string

John W Babich

http://www.w3.org/2001/XMLSchema#string

Klaus Kopka

http://www.w3.org/2001/XMLSchema#string

Tom Armor

http://www.w3.org/2001/XMLSchema#string

Uwe Haberkorn

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.

Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.

Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer.

Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.

Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

Tolerance of normal tissue to therapeutic irradiation.

Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance.

68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging.

P2888

s00259-014-2713-y

P304

1280-1292

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-014-2713-Y

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

41

http://www.w3.org/2001/XMLSchema#string

P50

Christian M. Zechmann

Ali Afshar-Oromieh

Boris Hadaschik

P577

2014-02-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260431033

http://www.w3.org/2001/XMLSchema#string

P698

24577951

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

4052014

http://www.w3.org/2001/XMLSchema#string